Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
PHASE3CompletedINTERVENTIONAL
Enrollment
825
Participants
Timeline
Start Date
July 31, 2006
Primary Completion Date
January 31, 2007
Study Completion Date
January 31, 2007
Conditions
HypercholesteremiaHyperlipidemia
Interventions
DRUG
MK-0524A
DRUG
ER Niacin
DRUG
Placebo
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00376584 - Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) | Biotech Hunter | Biotech Hunter